Equity analyst on why he remains a ‘skeptic’ on Biogen’s new Alzheimer’s drug

About This Source - CNBC Television

CNBC is an American pay television business news channel, which primarily carries business day coverage of U.S. and international financial markets. Following the end of the business day and on non-trading days, CNBC primarily carries financial and business-themed documentaries and reality shows.

As of February 2015, CNBC is available to approximately 93,623,000 pay television households (80.4% of households with television) in the United States.

Recent from CNBC Television:

  • ETF Edge, August 2, 2021
  • Square acquires Afterpay, shares rise after $29B all-stock deal
  • Why coffee prices have been on a wild ride
  • CNBC Television published this video item, entitled “Equity analyst on why he remains a ‘skeptic’ on Biogen’s new Alzheimer’s drug” – below is their description.

    The Food and Drug Administration on Monday approved Biogen’s Alzheimer’s disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer’s and the first new medicine for the disease in nearly two decades. The Massachusetts-based biotechnology company said Monday that aducanumab’s list price is $56,000 per year; $4,312 per infusion. Kevin Huang, senior equity analyst covering biotech and medtech at CFRA, joined “Squawk Box” on Tuesday to discuss.

    CNBC Television YouTube Channel

    Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

    Leave a Comment